How I Manage Acute Respiratory Failure in Patients with Hematological Malignancies

Elie Azoulay,Johan Maertens,Virginie lemiale

DOI: https://doi.org/10.1182/blood.2023021414

IF: 20.3

2024-01-18

Blood

Abstract:Acute respiratory failure (ARF) is common in hematological malignancies patients, notably those with acute leukemia, myelodysplastic syndrome, or allogeneic stem-cell transplantation. ARF is the leading reason for intensive care unit (ICU) admission, with a 35% case fatality. Failure to identify the ARF cause is associated with mortality. A prompt well-designed diagnostic workup is crucial. The investigations are chosen according to pre-test diagnostic probabilities, estimated by the DIRECT approach: D stands for delay, or time since diagnosis; I for pattern of immune deficiency; R and T for radiological evaluation; The "E" refers to clinical experience and the C to the clinical picture. Thorough familiarity with rapid diagnostic tests helps to decrease the use of bronchoscopy with bronchoalveolar lavage, which can cause respiratory-status deterioration in those hypoxemic patients. A prompt etiological diagnosis shortens the time on unnecessary empirical treatments, decreasing iatrogenic harm and costs. High-quality collaboration between intensivists and hematologists and all cross-disciplinary healthcare workers is paramount. All oxygen delivery systems should be considered to minimize invasive mechanical ventilation. Treatment of the malignancy is started or continued in the ICU under the guidance of the hematologists. The goal is to use the ICU as a bridge to recovery, with the patient returning to the hematology ward in sufficiently good clinical condition to receive optimal anticancer treatment.

hematology